Clostridium botulinum neurotoxins (BoNTs) are effective therapeutics for a variety of neurological disorders, such as strabismus, blepharospam, hemificial spasm, and cervical dystonia, because of the toxin's tropism for neurons and specific cleavage of neuronal soluble N-ethylmaleimide-sensitive fusion protein-attachment protein receptors (SNARE) proteins. Modifying BoNT to bind nonneuronal cells has been attempted to extend therapeutic applications. However, prerequisite to develop nonneuronal therapies requires the retargeting the catalytic activity of BoNTs to nonneuronal SNARE isoforms. Here, we reported the engineering of a BoNT derivative that cleaves SNAP23, a nonneuronal SNARE protein. SNAP23 mediates vesicle-plasma membrane fusion processes, including secretion of airway mucus, antibody, insulin, gastric acids, and ions. This mutated BoNT/E light chain LC/E(K 224 D) showed extended substrate specificity to cleave SNAP23, and the natural substrate, SNAP25, but not SNAP29 or SNAP47. Upon direct protein delivery into cultured human epithelial cells, LC/E(K 224 D) cleaved endogenous SNAP23, which inhibited secretion of mucin and IL-8. These studies show the feasibility of genetically modifying LCs to target a nonneuronal SNARE protein that extends therapeutic potential for treatment of human hypersecretion diseases.
SNAP23 ͉ SNAP25 ͉ SNARE proteins
Clostridium botulinum neurotoxins (BoNTs) are the most potent protein toxins for humans (1) . BoNTs elicit neuronal-specific flaccid paralysis by targeting neurons and cleaving neuronspecific soluble N-ethylmaleimide-sensitive fusion proteinattachment protein receptors (SNARE) proteins. BoNTs are organized into 3 functional domains: an N-terminal zinc-metalloprotease light chain (LC), a translocation domain (HCT), and a C-terminal receptor binding domain (HCR) (1, 2) . BoNTs bind luminal domains of synaptic vesicle proteins, upon the fusion of synaptic vesicles with the plasma membrane (3) (4) (5) . BoNTs are internalized into endosomes and upon acidification, the LC is translocated into the cytoplasm, where SNARE proteins are cleaved (1, 2) .
Mammalian neuronal exocytosis is driven by the formation of protein complexes between the vesicle SNARE, VAMP2, and the plasma membrane SNAREs, SNAP25 and syntaxin 1a (6) . There are 7 serotypes of BoNTs (termed A-G) that cleave specific residues on 1 of 3 SNARE proteins: serotypes B, D, F, and G cleave VAMP-2, serotypes A and E cleave SNAP25, and serotype C cleaves SNAP25 and syntaxin 1a (1) . Thus, neuronal specificity is based upon BoNT binding to neurons and cleaving neuronal isoforms of the SNARE proteins. For example, BoNT/A cleaves human SNAP25, but not the human nonneuronal isoform SNAP23 (7, 8) . The nonneuronal SNARE isoforms are involved in divergent cellular processes, including fusion reactions in cell growth, membrane repair, cytokinesis, and synaptic transmission (reviewed in 9).
The reversible nature of muscle function after BoNT intoxication that replace toxin-affected nerves with new nerves (10) has turned the BoNT from a deadly agent to therapies for neuromuscular conditions. As early as 1989, BoNT/A was approved by the FDA to treat strabismus, blepharospam, and hemificial spasm and then for cervical dystonia, cosmetic use, glabellar facial lines, and axillary hyperhidrosis (11) . BoNT/A efficacy in dystonia and other disorders related to involuntary skeletal muscle activity, coupled with a satisfactory safety profile, has prompted empirical/off-label use in a variety of secretions and pain and cosmetic disorders (12) .
The clinical use of BoNTs is limited to targeting inflictions affecting neuromuscular activity (11, 12) . Elucidation of the structure-function relationship of BoNTs has enabled the design of therapies that retarget BoNT to unique neurons and nonneuronal cells. Replacement of BoNT HCR domain with nerve growth factor, lectin from Erythrina cristagalli, or epidermal growth factors enable retargeting of BoNT/A to neuronal or nonneuronal cells such as nociceptive afferents and airway epithelium cells (13) (14) (15) . However, the selective cleavage of neuronal-specific SNARE proteins by BoNT has limited development of therapies in these nonneuronal systems. Prerequisite to develop therapies requires the retargeting of the catalytic activity of the BoNTs to nonneuronal SNARE isoforms. Here, we extend the substrate specificity of BoNT/E by engineering a catalytic derivative that cleaves the nonneuronal SNARE protein, SNAP23, as a platform to develop therapies for nonneuronal human secretory diseases (16, 17) .
Results
Previous studies identified residues 167-186 as the minimal, optimal peptide of SNAP25, a 206 amino acid protein, for LC/E in vitro cleavage (18) . SNAP25 (167-186) comprises 2 subsites that include a substrate binding ''B'' region and an active site ''AS'' region (Fig. 1A) . LC/E recognizes the P3 residue to facilitate alignment of the P2 and P1Ј residues of SNAP25. The S1Ј pocket of LC/E is formed by F 191 , T 159 , and T 208 with hydrophobic interactions between F 191 of LC/E and the P1Ј residue I 181 of SNAP25 (19) . The basic S2 pocket contains K 224 , which recognizes the P2 residue, D 179 , through a predicted salt bridge. Docking the P2 and P1Ј residues of SNAP25 into the active site pockets of LC/E aligns the scissile bond for cleavage (18, 19) .
Binz and coworkers reported that BoNT/E did not cleave human SNAP23 (8) , which provided a framework for defining SNAP isoform specificity of the BoNTs. Many of the residues that contributed to LC/E recognition of SNAP25 were conserved in human SNAP23, except This article is a PNAS Direct Submission. 1 To whom correspondence should be addressed. E-mail: jtb01@mcw.edu.
This article contains supporting information online at www.pnas.org/cgi/content/full/ 0903111106/DCSupplemental. the P2 residue of SNAP25, D 179 , is recognized by the basic S2 pocket of LC/E via the basic residue, K 224 , which contributes to LC/E substrate recognition (Fig. 1C, upper panel) . This allowed the hypothesis that ''the salt bridge between K 224 of LC/E and D 179 of SNAP25 contributes the ability of LC/E to cleave SNAP25 and that charge repulsion between K 224 of LC/E and the P2 residues of SNAP23, K 185 , contributes to the inability of LC/E to cleave SNAP23.'' To test this hypothesis, a point mutation, K 224 D, was introduced into LC/E and tested for the ability to cleave human SNAP23 ( 187 . SNAP25 isoforms include SNAP25a, SNAP25b, SNAP23a, SNAP23b, SNAP29, and SNAP47 (22, 23) . SNAP23 and SNAP25 mediate synaptic membrane fusion in nonneuronal and neuronal cells, respectively, whereas SNAP29 and SNAP47 have not been implicated in membrane fusion events. SNAP29 was shown to inhibit SNARE disassembly and was implicated in synaptic transmission (24) . Whereas the function of SNAP47 is not clear, SNAP47 can substitute for SNAP25 in SNARE complex formation and proteoliposome fusion. The substrate specificity of LC/E(K 224 D) on SNAP25 isoforms including SNAP23a, SNAP25b, SNAP29, and SNAP47 were tested. SNAP23b and SNAP25a were not tested because the a-b isoforms of SNAP23 and SNAP25 were identical at the LC/E predict the recognition of P site residues of SNAP23 by LC/E(K 224 D). Models were generated by SWISS-MODEL, using LC/E crystal structure (PDB:3d3x), and images were generated in PyMol. substrate recognition region (Fig. 4A) . LC/E(K 224 D) showed similar activity on both SNAP23 and SNAP25 (Fig. 4B ), but did not cleave SNAP29 and SNAP47. Wt-LC/E cleaved SNAP25 (Fig. 4C) , but not the other SNAP25 isoforms. The specificity of another LC/E K 224 mutation (K 224 A) on SNAP23 and SNAP25 was also characterized. LC/E (K 224 A) cleaved SNAP23 and SNAP25 with similar efficiencies, but at a slower rate than LC/E(K 224 D).
Next, the ability of LC/E(K 224 D) to cleave endogenous SNAP23 in HeLa cells was tested. Whereas a role for SNAP23 in constitutive exocytosis is not apparent (25) , SNAP23 contributes to regulated exocytosis (26) . Transfection of approximately 60% of a HeLa cell population with LC/E(K 224 D) resulted in the cleavage of approximately 45% of the SNAP23, whereas SNAP23 cleavage was not detected when HeLa cells were transfected with Wt-LC/E or a no plasmid control (Fig. S1 ). This (Fig. S1 B and C) . The inhibition was specific, because Wt-LC/E-transfected HeLa cells showed the same amount of mucin and IL-8 secretion as control cells and did not cleave endogenous SNAP23 (Fig. S1) .
To test the feasibility of using LC/E(K 224 D) as a protein therapy, recombinant LC/E(K 224 D) was delivered into HeLa cells, using digitonin. Recombinant LC/E(K 224 D) cleaved endogenous SNAP23 (Fig. 5A) , which inhibited TNF-␣-mediated mucin and IL-8 secretion (Fig. 5B and C) . Digitonin treatment , and SNAP47 (ClustalW2) in the regions corresponding to SNARE proteins that interact with the binding region and active sites region of LC/E. Indicated are conserved residues (*) and similar residues (:, .) among the SNAP25 isoforms. Cleavage site of SNAP25 by LC/E (arrow) and P site resides are indicated. Linear velocity assays of LC/E(K 224 D) (B) and Wt-LC/E (C) with the indicated isoforms of SNAP25. Five micromolar SNAP25 isoform was incubated with the indicated amounts of LC, subjected to SDS/PAGE and gels were stained with Coomassie. The amount of SNAP25 isoform cleavage was determined by densitometry. . After an overnight incubation, cells were washed and then incubated with serum free MEM media supplemented with 20 ng/mL TNF-␣ for 36 h when cell supernatants were collected and cell lysates were prepared. (A) Cell lysates were subjected to SDS/PAGE and LC/E expression and SNAP23 cleavage was measured by Western blot, using ␣-3Xflag antibody and ␣-SNAP23 antibody, respectively; * indicates migration of the SNAP23 cleavage product. Culture supernatants were assayed IL-8 (B) and mucin (C) secretion, using an ELISA, using 1.0 as a reference for cells treated with recombinant LC/E. also delivered Wt-LC/E into HeLa cells, but Wt-LC/E-treated HeLa cells, did not show detectable inhibition of mucin and IL-8 secretion and did not cleave endogenous SNAP23 (Fig. 5 ). This supports a role for SNAP23 in regulated exocytosis pathways in epithelial cells and indicates the utility of LC/E(K 224 D) as a research tool to study SNAP23-regulated exocytosis (26) .
Discussion
Understanding of substrate specificity of botulinum neurotoxins has enabled the engineering of a light chain derivative of BoNT/E with extended substrate specificity, providing a proof of principle to extend the clinical potential of BoNT therapy beyond neurological applications. Whereas airway mucus protects the epithelial lining by entrapping and clearing foreign debris, bacteria, and viruses from the airway by ciliary movement, a process termed mucociliary clearance (16, 17) , excessive airway mucus secretion, mucus hypersecretion, may cause mucus accumulation that is associated with human clinical conditions such as asthma and chronic obstructive pulmonary disease where mucus accumulation contributes to respiratory diseases. Mucus secretion is a regulated process coordinated by several molecules, including SNARE proteins, myristoylated alanine-rich C kinase substrate (MARCKS), and Munc proteins, which coordinate the docking of mucin containing vesicles with the secretory cell plasma membrane for exocytosis (16, 17) . Targeting SNAP23 by a substrate modified BoNT may reduce the secretion processes of hypersecretion syndromes. A SNAP23-specific BoNT may also be targeted for other therapeutic applications that include diabetes and inflammatory and immune disorders which include a hypersecretory component (27, 28) .
Alignment and biochemical analyses allow prediction of the mechanism for the catalytic activity of Wt-LC/E and LC/ E(K 224 D) on SNAP25 isoforms. The low overall homology within the active site regions of SNAP29 and SNAP47 to SNAP25 and the lack of an isoleucine at the P1Ј site explain the inability of Wt-LC/E and LC/E(K 224 D) to cleave SNAP29 and SNAP47. In contrast, the overall homology between SNAP23 and SNAP25 is high, except at the P2, P2Ј and P3Ј residues with the most dramatic change at the P2 residue where SNAP25 contains an aspartate and SNAP23 contains a lysine. Thus, 1 reason for the inability of Wt-LC/E to cleave SNAP23 may be because of electrostatic repulsion of the P2 residue lysine within SNAP23 by K 224 of LC/E. This may destabilize the S2 pocket and affect alignment of the P1Ј residue into the S1Ј pocket. The ability of LC/E(K 224 D) to cleave SNAP23 may be because of the introduction a salt bridge between the P2 residue Lys of SNAP23 and the mutated S2 pocket residue D 224 . LC/E(K 224 D) also retained the ability to cleave SNAP25, although at a rate that was approximately 10-fold slower than Wt-LC/E. This suggests that the repulsion between the P2 residue aspartate of SNAP25 and the mutated S2 pocket residue D 224 was not sufficient to inhibit sessile bond cleavage by LC/E(K 224 D). Because LC/E(K 224 D) cleaved SNAP25 and SNAP23, but at a reduced rate relative to LC/E(K 224 D), both charge and size of the R-group at residue 224 contribute to optimal scissile bond cleavage. Overall, the biochemical properties of LC/E and LC/E-K 224 derivatives are consistent with P2 residue-S2 pocket residue interactions contributing to the efficiency of sessile bond cleavage. Whereas the ability of native LC/E to bind SNAP23 has not been determined, kinetic values for LC/E and SNAP25 and LC/E(K 224 D) and SNAP23 are within 2-fold, indicating similar binding affinities. Alignment of SNAP25 and SNAP23 within the LC/E binding region (Fig. 1 ) is nearly identical with 7 of 8 residues identical and the nonidentical pair being T:A; a conserved substitution pair, which also supports similar binding affinities of LC/E for SNAP25 and SNAP23.
SNARE proteins are key proteins in membrane fusion and trafficking within neuronal secretory pathways (9) . The use of BoNT has contributed to the understanding vesicle fusion and neurotransmitter release mechanisms in neuronal cells. The ability of a BoNT derivative to cleave nonneurological SNAREs may provide a useful tool to investigate intracellular vesicular trafficking and the mechanism of membrane fusion in nonneuronal systems.
Although BoNT/A could be considered the logical serotype to be engineered for various applications because of its wide clinical applications, analyses of the mechanisms of SNAP25 recognition indicate that LC/A requires a longer substrate for optimal SNAP25 recognition with a greater number of residue interactions than LC/E (19) . The less-complex SNAP25-LC/E interactions make BoNT serotype E amenable for engineering to modify substrate recognition. In addition, alignment of human SNAP25 and SNAP23 showed that these proteins had a high level of homology at the P3 and P1Ј sites that are involved in SNAP25 recognition by LC/E. Thus, BoNT/E is a useful platform to engineer mutations that effect SNARE protein recognition. The successful delivery of LC/E(K 224 D) into cells to inhibit IL-8 and mucin secretion supports a role for LC/E(K 224 D) as a research tool and also shows the potential for therapy to regulate human hypersecretion diseases such as asthma and inf lammatory diseases. The therapeutic specificity of LC/ E(K 224 D) would be based upon the receptor binding component, as described for toxin chimeras, such as diphtheria toxin A fragment-IL2 (29) and Exotoxin A fragment-IgG variable region fragment (30) . In conclusion, the current study shows proof of principle for altered substrate specificity to extend the application of BoNTs beyond neurological inflictions.
Methods
Molecular Modeling. Molecular modeling was performed using SWISS-MODEL. The structure of LC/E-SNAP25 (146 -202) complex was obtained as described (18) , using the crystal structure of LC/E (PDB:3d3x). The structure of LC/ E(K 224 D)-SNAP23 was modeled using LC/E-SNAP25 complex structure as template, using PyMol. Data presented are the average of experiments performed at least 3 times.
Plasmid Construction and Protein Expression. BoNT LC/E expression vector was constructed by amplifying DNA encoding LC/E (1-400) of C. botulinum serotype E Belugaand subcloned into pET-15b. For transfection experiments, LC/E (1-400) was also subcloned into pEGFP vector to generate an EGFP-LC/E (1-400) fusion protein expressed under the CMV promoter. Expression vectors for SNAP23 (152-211), SNAP29 (202-258), and SNAP47 (406 -464), the protein equivalents of SNAP25 (145-206), were constructed by amplifying the cDNA template: human SNAP23 (ATCC, 2900640), SNAP29(ATCC, 10700609), and SNAP47(ATCC, 10468826) by PCR and subcloning into pGEX-2T. Site-directed mutagenesis was performed using QuikChange (Stratagene). Protein expression and purification were performed as previously described (18) .
Cleavage of SNARE Proteins by LC/E and LC/E(K 224 D). Linear velocity reaction.
Reactions contained (10 L): 5 M human SNARE proteins, 10 mM Tris-HCl (pH 7.6) with 20 mM NaCl, and the indicated amounts of LC/E and LC/E(K 224 D). Reactions were incubated for 10 min at 37°C, subjected to SDS/PAGE, and gels were stained with Coomassie. The amount of SNARE protein cleavage was determined by densitometry. Kinetic parameters. K m and kcat determinations were made for Wt-LC/E and LC/E derivatives using SNAP25 isoforms. LC concentrations were adjusted to cleave Ͻ10% substrate at several concentrations of substrate (1.5ϳ18 M SNARE protein). Reactions were carried out at 37°C for 10 min, subjected to SDS/PAGE, and the amount of cleaved product was calculated by densitometry. Reaction velocity versus substrate concentration was fit to the Michaelis-Menten equation, using Lineweaver-Burk plots, using SigmaPlot IX.
LC/E and LC/E(K 224 D) Activity in Human Cultured Epithelial Cells. Cell transfection. HeLa cells were cultured in 6-well plates in MEM supplemented with 10% newborn calf serum. Subconfluent cells were transfected with 0.5 or 1.0 g indicated plasmid using Lipofectamine LTX (GIBCO/BRL). Protein delivery. Protein delivery was performed as described (31) with modification. HeLa cells were permeabilized with 1 mL/well of permeabilization buffer containing 30 M digitonin for 7 min and then incubated in permeabilization buffer with and without the indicated LC. Protein Secretion Assays. After an overnight incubation, transfected and protein-delivered cells were incubated in 2 mL serum-free MEM containing 20 ng/mL TNF-␣. After 36 h, 1.5 mL supernatant was collected, centrifuged at 13,000 ϫ g for 1 min, and assayed for secreted mucin and IL-8, using an ELISA. Supernatants (150 L) were mixed with 50 L of 0.2 M Na 2CO3 (pH 9.6) and added to 96-well plates and incubated overnight at 4°C. Plates were washed and locked with 50 mM Na 2CO3 (pH 9.6) buffer containing 1% (wt/vol) BSA. Plates were washed and incubated with 100 L ␣-mucin IgG (1/200 dilution, Abcam) or ␣-IL-8 IgG (1/200 dilution, Abcam) for 1 h at RT. Plates were washed 3 and incubated with ␣-mouse horseradish peroxidase-conjugated antibody (1:10,000 dilution, Pierce) for 1 h at RT. Plates were washed and developed with 100 L Ultra-TMB (Pierce) for 20 min at RT and quenched with 100 L of 1M H2SO4. A450 was expressed as fraction relative to secreted mucin or IL-8 in control supernatants. Cleavage of SNAP23. Lysates from cells incubated with TNF-␣ for 36 h were assayed for LC/E and LC/E (K 224 D)-mediated a cleavage of endogenous SNAP23, using ␣-SNAP23 mouse IgG (Abcam) by Western blot analysis (18) .
